Nasal Polyps (Nasal Polyposis) Pipeline Report: Encapsulates all the Dormant and Discontinued Pipeline Projects

Nasal polyps (Nasal polyposis) is an inflammatory condition develops in the nasal lining of nose. They are non-cancerous growths. Signs and symptoms include runny nose, postnasal drip, headache, snoring and loss of sense of taste. Risk factors include asthma, aspirin sensitivity, cystic fibrosis, Churg-strauss syndrome and allergic fungal sinusitis. Treatment includes steroid medications. Nasal Polyps (Nasal Polyposis) – Therapeutics DevelopmentPipeline Overview Number of Products under Development for Nasal Polyps (Nasal Polyposis), H1 2019


Report Source:


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Purchase this report at:

Reasons To Buy

  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • AnaptysBio Inc
  • Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Idorsia Pharmaceutical Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Novartis AG
  • OptiNose US Inc
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Suzhou Connect Biopharmaceuticals Ltd

Got a question; ask us at: